Join us in Washington, DC
Join us in Washington, DC
June 15-19, 2025
Join us at the DIA 2025 Global Annual Meeting—the ultimate hub for industry visionaries, regulators, government leaders, academics, innovators, and patients. Set in the dynamic city of Washington DC, this premier event invites global stakeholders to unite, collaborate, and ignite transformation in the life sciences.
Register NowSchedule-at-a-Glance
Stay tuned for updates and start planning your ultimate experience! Explore key sessions, must-see events, and networking opportunities—all in one place.
Announcements and Highlights
-
About
DIA 2025 is more than a meeting: Focus on the future of health.
Learn More -
Call for Posters
The Call for Professional and Student Posters is Open!
Learn More -
Exhibits is Open!
Secure Your Space Today and Make a Lasting Impression!
Exhibit With Us -
Registration is Open!
Register Today for Early Bird Savings for 2025!
Learn More -
Schedule-at-a-Glance
Quick View: Key Sessions, Workshops, and Networking Highlights
Download Today! -
Social
Follow us on Twitter, Facebook, and LinkedIn @DrugInfoAssn and #DIA2025 for continuous updates!
Follow Us
Customer Testimonials
"The DIA meeting is so incredibly valuable from a professional standpoint for the networking, the content…its really super valuable, it's a must-attend meeting."
"The way that DIA's Global Annual Meeting is different from other industry events is that it offers something for everyone. It’s the most democratic congress or association to which I belong, there are colleagues from every aspect of bio-pharmaceutical product development, and you learn a lot and it's just a lot of fun."
"I love the Global Annual Meeting because it does bring together different disciplines, different experts from industry, from academia, from regulators to address the topics at hand and to bring that and make that available to attendees. "
Program Committee
-
Linda Akunne, MPH • Chief, Project Management Staff, ORO, OND, CDER
FDA, United States -
Venkatraman Balasubramanian, PhD, MBA • Healthcare and Life Sciences Strategic Advisor
VB Insights, LLC, United States -
Greg Ball, PhD • Safety Data Scientist
ASAPprocess, United States -
Amy Bertha • Executive Director, Regulatory Policy and Science
Bayer, United States -
Sanghita Bhattacharya, PhD • Director Data Science , Feasibility and Analytics, Clinical Operations
Johnson & Johnson Innovative Medicine, United States -
Asia Blackwell • Consumer Safety Officer
FDA, United States -
Claire Blanchette, PMP • Executive Drug Development Program Leader
Consultant, United States -
Tywnia Brewton • Executive Director, Human Resources
Astellas , United States -
James Buchanan, PharmD • President
Covilance LLC, United States -
Mandy Kaur Budwal-Jagait, MSc • Head of GCP and Lead Senior GCP Inspector
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Meghana Chalasani, MHA • Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
FDA, United States -
Joan Chambers • Senior Consultant
Tufts CSDD, United States -
Rachel Chasse, MS • Associate Director, Digital Science Strategy
AbbVie, United States -
Christine Colvis, PhD • Director, Drug Development Partnership Programs
National Center for Advancing Translational Sciences (NCATS), United States -
Karen Correa, PhD • Vice President, Head of Global Clinical Operations
Takeda, United States -
Solange Corriol-Rohou, DrMed, MD, PhD • Senior Director, Global Regulatory Affairs & Policy, R&D, Europe
AstraZeneca , France -
Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy
University of Illinois at Chicago, United States -
Alysha Croker, PhD • Director, Centre for Policy, Pediatrics and International Collaboration, BRDD
Health Canada, Canada -
Victoria DiBiaso, BSN, MPH, RN • Global Head, Patient Informed Development and Health Value Translation
Sanofi, France -
Megan Doyle, JD, MPH • Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States -
Nancy A Dreyer, PhD, MPH, FISPE • Founder
Dreyer Strategies LLC, United States -
Joseph Dustin • Founder and Managing Partner
eClinical Consulting, United States -
Jennifer Emerson, PhD, MPH, RN, PMP • Head Quality Analytics & Risk Management
Boehringer Ingelheim, Germany -
Andrew Emmett, MPH • FDA Liaison | US Regulatory Policy and Global Intelligence
Pfizer Inc, United States -
Ron Fitzmartin, PhD, MBA • Senior Advisor, Office of Regulatory Operations, CBER
FDA, United States -
Celeste Frankenfeld Lamm, PhD • Senior Director, Global Regulatory Affairs – CMC
Merck Sharp & Dohme LLC , United States -
Danielle Friend Economo, PhD • Senior Director, US Head Regulatory Policy and Intelligence
Johnson & Johnson Innovative Medicine, United States -
David Fryrear, MS • Executive Vice President and Head of Quality Assurance
Astellas, United States -
Cheryl Grandinetti, PharmD • Associate Director for Clinical Policy, CDER/OC/OSI/DCCE
FDA, United States -
Courtney Granville, PhD, MPH • Chief Scientific Officer
GO2 For Lung Cancer, United States -
Lani Hashimoto • Associate Director, Patient Engagement
Novartis Pharmaceuticals Corporation, United States -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Cammilla Horta Gomes, MA, MPharm • Latam Regulatory Policy Lead
Roche, Brazil -
Stacy Hurt, MBA, MHA • Chief Patient Officer
Parexel , United States -
Huong Huynh, PhD • Director of Regulatory Science
Critical Path Institute, United States -
Emily (Xianghong) Jing, PhD • Associate Director for Scientific Coordination, OBP, OPQ, CDER
FDA, United States -
Jeremy Jokinen, PhD, MS • Vice President and Head, Safety Evidence and Sciences
Bristol-Myers Squibb Company, United States -
Dominique Lagrave, PharmD • Senior Vice President of Regulatory Innovation
Accumulus Synergy, United States -
Cathryn C Lee, MSN • Director, Office of Program Operations, PDIMS, OND, CDER
FDA, United States -
Jingyu (Julia) Luan, PhD • Executive Regulatory Science Director, BioPharmaceuticals R&D
AstraZeneca, United States -
Demetra Macheras, MBA • Director, Regulatory Policy and Intelligence - Regulatory Affairs
AbbVie, United States -
Nicole Mahoney, PhD • Executive Director US Regulatory Policy & Intelligence
Novartis Pharmaceuticals Corporation, United States -
Lindsay McNair, MD, MPH, MS • Principal Consultant
Equipoise Consulting, United States -
Melodi J McNeil, MS, RPh • Director, Regulatory Policy and Intelligence
AbbVie, United States -
David Meats • Director, Regulatory Services Management
Certara, United States -
Timothe Menard, PharmD, MSc • Global Head, Quality Excellence Digital | Bioethics Coach (Data Ethics)
F. Hoffmann-La Roche Ltd, Switzerland -
Pallavi Mishra-Kalyani, PhD, MS • Deputy Division Director, DBV, OB, CDER
FDA, United States -
May F Mo, MBA, MS • Executive Director, Biostatistics
Amgen, United States -
Monica Munoz, PharmD, PhD • Division Director, Division of Pharmacovigilance-I, OSE, CDER
FDA, United States -
Lauren Oliva, PharmD, RPh • US Lead, Global Regulatory Policy
Biogen, United States -
Y. Veronica Pei, MD, MEd, MPH • Acting Associate Director, Biomedical Informatics and Regulatory Review Science
FDA, United States -
Vada A. Perkins, DrSc, MSc • Vice President, Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim, United States -
Ranjini Prithviraj, PhD, PMP • Director, Global Medical Affairs, Publication Management
Regeneron, United States -
Kim Ribeiro, MS •
United States -
Margaret Richards, PhD, MPH • Executive Director, Solutions
Panalgo, United States -
Elizabeth Rosenkrands-Lange, MPH, MS • Senior Director/ Head of US Regulatory Scientific Policy
EMD Serono, Part of Merck KGaA, Darmstadt, Germany, United States -
Cynthia Rothblum-Oviatt • Science Policy Analyst, Rare Disease Team, OND, CDER
FDA, United States -
Leslie Sam • President
Leslie Sam and Associates, LLC, United States -
Earl Seltzer, MBA • Senior Director, Partnerships and Innovation
CTI, United States -
Anjali Shah, PharmD • Executive Director, Business Capabilities and Innovation, WWPS
Bristol-Myers Squibb Company, United States -
Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences
University of Southern California School of Pharmacy, United States -
Elizabeth Somers, MS • Executive Director, Global Project and Alliance Management
Merck Sharp & Dohme LLC, United States -
Benjamin Stevens, PhD, MPH • Director CMC Policy and Advocacy
GlaxoSmithKline, United States -
Nancy Linda Styple • Project Management Leader
Bayer AG, United States -
Ling Su, PhD • Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China -
Alec Thompson, PharmD, MS • Senior Product Manager, Oncology
Gilead Sciences, United States -
Michael Torok, PhD • Vice President, Global Head of Quality Assurance Programs
Genentech, A Member of the Roche Group, United States -
Phil Tregunno • Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Yoshiaki Uyama, PhD, RPh • Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
James Valentine, JD, MHS • Director
Hyman, Phelps & McNamara, PC, United States -
James Wabby, MHS • Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States -
Paula Walker, MA • Global Head of Risk Based Quality Management
Roche Products Ltd., United Kingdom -
Robin Whitsell • President
Whitsell Innovations, Inc., United States -
Amira Younes • Director, Global Regulatory Policy EEMEA
MSD, United Arab Emirates
Stay Connected!
Sign up for our newsletter to get the latest updates, exclusive insights, and special offers delivered straight to your inbox. Be the first to know about upcoming events, new releases, and more. Join our community today!
